ArticleBiogerontology2025
Regulation of endothelial cell senescence via the miR-217/FOXO3 axis.
Article in Biogerontology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- FOXO: a key target in regulating aging and age-related diseases.Biogerontology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The accumulation of senescent endothelial cells within the endothelium leads to vascular dysfunction. Independent studies have linked miR-217, a senescence-associated microRNA and FOXO3, a longevity factor, to cellular senescence in different study models. However, their roles and direct interaction in endothelial replicative senescence (RS) remain to be investigated. This study sought to investigate the role of miR-217/FOXO3 axis in endothelial cell senescence. Young and RS HUVEC models were established to determine the differential mRNA and protein expressions of miR-217 and FOXO3 by RT-qPCR and immunoblotting. HUVECs were transfected with miR-217 mimic duplexes and hairpin inhibitors to evaluate the effects of elevated or reduced miR-217 expressions in endothelial health. FOXO3 was also stably knocked down using a lentiviral vector and rescue experiments were performed. RS HUVECs showed elevated senescence markers and miR-217 but decreased FOXO3 expressions. Dual-luciferase reporter assay confirmed FOXO3 as a direct miR-217 target. MiR-217 overexpression reduced FOXO3 but increased p16INK4a protein levels and impaired angiogenic potential in young HUVECs, suggesting that miR-217 promotes endothelial senescence and hampers angiogenesis by targeting FOXO3. Suppressing miR-217 increased FOXO3 expression in both RS and early-stage senescence (ES) HUVECs. However, ES but not RS HUVECs exhibited improved angiogenic potential. Meanwhile, FOXO3 knockdown increased miR-217 and p16INK4a expressions, indicating that FOXO3 loss drives endothelial senescence. However, transfection of FOXO3 knockdown cells with miR-217 inhibitor could only partially recover HUVECs angiogenic potential, suggesting that FOXO3 is critical for maintaining endothelial function. Collectively, these results showed that endothelial senescence and angiogenic potential are mediated through the crucial interaction of miR-217/FOXO3.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.